NASDAQ:AXON - Axovant Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.20 -0.03 (-2.44 %)
(As of 05/25/2018 03:47 AM ET)
Previous Close$1.20
Today's Range$1.18 - $1.2438
52-Week Range$1.02 - $27.98
Volume394,681 shs
Average Volume1.16 million shs
Market Capitalization$132.58 million
P/E Ratio-0.66
Dividend YieldN/A
Beta-0.37

About Axovant Sciences (NASDAQ:AXON)

Axovant Sciences logoAxovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM behavior disorder in patients with LBD. In addition, it focuses on developing RVT-103, a combination of donepezil and a peripheral muscarinic receptor antagonist; and RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXON
CUSIPN/A
Phone44-20-3318-9708

Debt

Debt-to-Equity Ratio0.45
Current Ratio4.58
Quick Ratio4.58

Price-To-Earnings

Trailing P/E Ratio-0.66
Forward P/E Ratio-0.54
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.26 per share
Price / Book0.95

Profitability

EPS (Most Recent Fiscal Year)($1.82)
Net Income$-180,950,000.00
Net MarginsN/A
Return on Equity-168.63%
Return on Assets-102.29%

Miscellaneous

Employees69
Outstanding Shares107,790,000

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences (NASDAQ:AXON) posted its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.12. View Axovant Sciences' Earnings History.

When is Axovant Sciences' next earnings date?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, June, 12th 2018. View Earnings Estimates for Axovant Sciences.

What price target have analysts set for AXON?

11 brokers have issued 1-year target prices for Axovant Sciences' shares. Their predictions range from $2.50 to $30.00. On average, they expect Axovant Sciences' stock price to reach $14.75 in the next twelve months. View Analyst Ratings for Axovant Sciences.

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:
  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/14/2018)
  • 2. Cowen Inc analysts commented, "We maintain our BUY rating and $25 PT for SVRA shares." (2/13/2018)
  • 3. HC Wainwright analysts commented, "We hosted a conference call with a medical physicist on October 17, 2017. The consultant highlighted a number of key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC as well as main differences between ViewRay’s low-T MRIdian technology and competitor Elekta’s yet-to-be approved High- T Unity system. Replay information available upon request. KeyPoints High-T vs. Low-T. While in the context of a diagnosis, a high-T system would surely lead to greater image resolution, the low-T system appears more suitable in the treatment phase where the key lies in the ability to locate the patient’s tumor in a dynamic way. Image quality, it turns out, can be improved through various techniques according to our consultant." (10/19/2017)

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:
  • Dr. Gregory M. Weinhoff, Chief Financial Officer (Age 47)
  • Dr. Pavan Cheruvu, Chief Exec. Officer
  • Mr. Michael Adasczik, Principal Accounting Officer (Age 44)
  • Mr. Jonathan Neely, Head of Investor Relations & Corp. Communications
  • Ms. Marianne L. Romeo Dinsmore, Head of Global Transactions & Risk Management (Age 50)

When did Axovant Sciences IPO?

(AXON) raised $251 million in an IPO on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Has Axovant Sciences been receiving favorable news coverage?

News stories about AXON stock have trended somewhat positive on Friday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Axovant Sciences earned a media sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Axovant Sciences' major shareholders?

Axovant Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.79%), Millennium Management LLC (1.23%), A.R.T. Advisors LLC (0.39%) and JPMorgan Chase & Co. (0.17%). Company insiders that own Axovant Sciences stock include David Hung, George Bickerstaff and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Which institutional investors are buying Axovant Sciences stock?

AXON stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, George Bickerstaff and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $1.20.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $132.58 million. The biotechnology company earns $-180,950,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. Axovant Sciences employs 69 workers across the globe.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (AXON)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  241 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Axovant Sciences (NASDAQ:AXON) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Axovant Sciences in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 1,129.17%. The high price target for AXON is $30.00 and the low price target for AXON is $2.50. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.362.362.33
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.75$14.75$14.75$14.6818
Price Target Upside: 1,129.17% upside714.92% upside714.92% upside174.94% upside

Axovant Sciences (NASDAQ:AXON) Consensus Price Target History

Price Target History for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ:AXON) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018CowenReiterated RatingHoldHighView Rating Details
2/13/2018OppenheimerReiterated RatingHoldHighView Rating Details
1/10/2018Chardan CapitalUpgradeSell ➝ Neutral$2.50 ➝ $2.50LowView Rating Details
12/21/2017Jefferies GroupDowngradeBuy ➝ Hold$6.00HighView Rating Details
12/1/2017HC WainwrightReiterated RatingBuy$11.00MediumView Rating Details
11/10/2017Piper Jaffray CompaniesReiterated RatingHoldN/AView Rating Details
11/1/2017Robert W. BairdReiterated RatingHold$6.00N/AView Rating Details
9/26/2017Evercore ISIReiterated RatingOutperform$30.00 ➝ $9.00HighView Rating Details
9/26/2017JMP SecuritiesReiterated RatingOutperform$36.00 ➝ $19.00N/AView Rating Details
9/26/2017UBSDowngradeOutperform ➝ Market PerformN/AView Rating Details
6/14/2017CIBCBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.00HighView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Axovant Sciences (NASDAQ:AXON) Earnings History and Estimates Chart

Earnings by Quarter for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ:AXON) Earnings Estimates

2018 EPS Consensus Estimate: ($1.87)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.55)($0.53)($0.54)
Q2 20182($0.65)($0.52)($0.59)
Q3 20182($0.54)($0.22)($0.38)
Q4 20182($0.47)($0.26)($0.37)

Axovant Sciences (NASDAQ AXON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/12/2018        
2/9/2018Q3 2018($0.54)ViewN/AView Earnings Details
11/2/2017Q2 2018($0.55)($0.64)ViewN/AView Earnings Details
8/7/2017Q1 2018($0.53)($0.6510)ViewN/AView Earnings Details
6/13/20173/31/2017($0.51)($0.53)ViewN/AView Earnings Details
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
11/7/2016Q2 2017($0.40)($0.43)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Axovant Sciences (NASDAQ:AXON) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Axovant Sciences (NASDAQ AXON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 72.40%
Institutional Ownership Percentage: 14.83%
Insider Trading History for Axovant Sciences (NASDAQ:AXON)
Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Axovant Sciences (NASDAQ AXON) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/27/2018George BickerstaffDirectorBuy25,000$1.50$37,500.00View SEC Filing  
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50539,375View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.9853,937View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.002,300View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Axovant Sciences (NASDAQ AXON) News Headlines

Source:
DateHeadline
-$0.39 Earnings Per Share Expected for Axovant Sciences (AXON) This Quarter-$0.39 Earnings Per Share Expected for Axovant Sciences (AXON) This Quarter
www.americanbankingnews.com - May 14 at 5:19 AM
Axovant Sciences (AXON) Given Consensus Rating of "Hold" by BrokeragesAxovant Sciences (AXON) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 6 at 10:31 AM
Axovant Sciences (AXON) Upgraded to "Hold" by ValuEngineAxovant Sciences (AXON) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
Police Body Cameras Could Get Facial Recognition TechnologyPolice Body Cameras Could Get Facial Recognition Technology
finance.yahoo.com - April 27 at 7:16 AM
Axovant Sciences (AXON) Stock Rating Lowered by BidaskClubAxovant Sciences (AXON) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 2:21 PM
Axovant Sciences (AXON) Lifted to Hold at BidaskClubAxovant Sciences (AXON) Lifted to Hold at BidaskClub
www.americanbankingnews.com - April 13 at 4:55 PM
Axovant Sciences Ltd (AXON) Receives Average Recommendation of "Hold" from AnalystsAxovant Sciences Ltd (AXON) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 11 at 8:48 AM
Zacks: Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.39 EPSZacks: Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.39 EPS
www.americanbankingnews.com - April 9 at 7:19 PM
BidaskClub Downgrades Axovant Sciences (AXON) to SellBidaskClub Downgrades Axovant Sciences (AXON) to Sell
www.americanbankingnews.com - April 7 at 10:55 AM
ValuEngine Lowers Axovant Sciences (AXON) to Strong SellValuEngine Lowers Axovant Sciences (AXON) to Strong Sell
www.americanbankingnews.com - April 3 at 6:58 PM
Axovant Sciences (AXON) Earns Hold Rating from Robert W. BairdAxovant Sciences (AXON) Earns Hold Rating from Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM
Axovant Sciences (AXON) Rating Lowered to Strong Sell at ValuEngineAxovant Sciences (AXON) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 31 at 3:48 PM
Chardan Capital Upgrades Axovant Sciences (AXON) to "Neutral"Chardan Capital Upgrades Axovant Sciences (AXON) to "Neutral"
www.americanbankingnews.com - March 29 at 5:16 PM
Axovant Sciences (AXON) Rating Increased to Sell at ValuEngineAxovant Sciences (AXON) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 8:44 PM
 Analysts Expect Axovant Sciences Ltd (AXON) Will Post Earnings of -$0.53 Per Share Analysts Expect Axovant Sciences Ltd (AXON) Will Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - March 23 at 7:26 PM
Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over AxovantPair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant
finance.yahoo.com - March 23 at 9:07 AM
Axovant Sciences Ltd (AXON) Receives Consensus Recommendation of "Hold" from AnalystsAxovant Sciences Ltd (AXON) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 17 at 9:04 AM
Hudson Bay Capital Management LP Purchases New Position in Axovant Sciences Ltd (AXON)Hudson Bay Capital Management LP Purchases New Position in Axovant Sciences Ltd (AXON)
www.americanbankingnews.com - March 2 at 12:49 PM
Insider Buying: Axovant Sciences Ltd (AXON) Director Buys 25,000 Shares of StockInsider Buying: Axovant Sciences Ltd (AXON) Director Buys 25,000 Shares of Stock
www.americanbankingnews.com - March 1 at 10:44 PM
Axovant Sciences (AXON) PT Raised to $37.00Axovant Sciences (AXON) PT Raised to $37.00
www.americanbankingnews.com - February 28 at 7:24 PM
Axovant Sciences (AXON) "Hold" Rating Reiterated at OppenheimerAxovant Sciences' (AXON) "Hold" Rating Reiterated at Oppenheimer
www.americanbankingnews.com - February 18 at 10:22 PM
 Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.48 EPS Brokerages Expect Axovant Sciences Ltd (AXON) to Post -$0.48 EPS
www.americanbankingnews.com - February 17 at 9:08 PM
FY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by AnalystFY2018 EPS Estimates for Axovant Sciences Ltd (AXON) Lifted by Analyst
www.americanbankingnews.com - February 15 at 11:40 AM
Axovant Sciences (AXON) Downgraded by Zacks Investment Research to "Hold"Axovant Sciences (AXON) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 14 at 6:00 PM
AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences ... - Business Wire (press release)AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences ... - Business Wire (press release)
www.businesswire.com - February 14 at 3:16 PM
AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. InvestorsAXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors
finance.yahoo.com - February 14 at 3:16 PM
Axovant Sciences Ltd to Post FY2018 Earnings of ($2.10) Per Share, Jefferies Group Forecasts (AXON)Axovant Sciences Ltd to Post FY2018 Earnings of ($2.10) Per Share, Jefferies Group Forecasts (AXON)
www.americanbankingnews.com - February 14 at 11:38 AM
Is This the End of Axovant?Is This the End of Axovant?
www.msn.com - February 14 at 5:22 AM
Axovant Sciences (AXON) Rating Reiterated by CowenAxovant Sciences (AXON) Rating Reiterated by Cowen
www.americanbankingnews.com - February 13 at 8:08 PM
Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD ... - NasdaqHealth Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD ... - Nasdaq
www.nasdaq.com - February 13 at 5:25 AM
Health Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD,AVEO - NasdaqHealth Care Sector Update for 02/12/2018: AXON,UTHR,NVO,FOLD,AVEO - Nasdaq
www.nasdaq.com - February 12 at 3:15 PM
Axovant Stock Tumbles After Sweeping Leadership Changes - Wall Street JournalAxovant Stock Tumbles After Sweeping Leadership Changes - Wall Street Journal
www.wsj.com - February 12 at 3:15 PM
Axovant shares slide 21% premarket on news of CEO, COO departures - MarketWatchAxovant shares slide 21% premarket on news of CEO, COO departures - MarketWatch
www.marketwatch.com - February 12 at 3:15 PM
Axovant Shares Crater as CEO and President Both ResignAxovant Shares Crater as CEO and President Both Resign
finance.yahoo.com - February 12 at 3:15 PM
Axovant Sciences CEO David Hung resigns, shares tumbleAxovant Sciences CEO David Hung resigns, shares tumble
finance.yahoo.com - February 12 at 3:15 PM
[$$] Axovant Stock Tumbles After Sweeping Leadership Changes[$$] Axovant Stock Tumbles After Sweeping Leadership Changes
finance.yahoo.com - February 12 at 3:15 PM
Axovant shares slide 21% premarket on news of CEO, COO departuresAxovant shares slide 21% premarket on news of CEO, COO departures
finance.yahoo.com - February 12 at 3:15 PM
Zacks: Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.49 Per ShareZacks: Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.49 Per Share
www.americanbankingnews.com - January 31 at 11:10 PM
Axovant Sciences (AXON) Rating Increased to Buy at Zacks Investment ResearchAxovant Sciences (AXON) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 31 at 7:18 PM
This Mornings Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen - PR Newswire (press release)This Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen - PR Newswire (press release)
www.prnewswire.com - January 31 at 3:15 PM
Axovant Sciences Ltd (AXON) Given Average Recommendation of "Hold" by BrokeragesAxovant Sciences Ltd (AXON) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 26 at 8:44 AM
 Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share Brokerages Anticipate Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - January 15 at 1:10 AM
CBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall - NasdaqCBMG Giving Back Its Gains, ARNA To Report Data In Q1, AXON Continues To Fall - Nasdaq
www.nasdaq.com - January 12 at 3:38 PM
Axovant Sciences (AXON) Rating Lowered to Market Perform at CowenAxovant Sciences (AXON) Rating Lowered to Market Perform at Cowen
www.americanbankingnews.com - January 12 at 8:02 AM
After A Freefall In Axovant Shares, Chardan UpgradesAfter A Freefall In Axovant Shares, Chardan Upgrades
finance.yahoo.com - January 10 at 3:41 PM
Implied Volatility Surging for Axovant Sciences (AXON) Stock OptionsImplied Volatility Surging for Axovant Sciences (AXON) Stock Options
finance.yahoo.com - January 10 at 11:22 AM
Heres Why Axovant Sciences Dropped TodayHere's Why Axovant Sciences Dropped Today
www.fool.com - January 9 at 11:08 AM
GoPro, Axovant Sciences Plunge into Monday’s 52-Week Low ClubGoPro, Axovant Sciences Plunge into Monday’s 52-Week Low Club
www.marketwatch.com - January 9 at 11:08 AM
CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin StudyCORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
finance.yahoo.com - January 9 at 11:08 AM
38 Stocks Moving In Mondays Mid-Day Session - Benzinga38 Stocks Moving In Monday's Mid-Day Session - Benzinga
www.benzinga.com - January 8 at 3:46 PM

SEC Filings

Axovant Sciences (NASDAQ:AXON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Axovant Sciences (NASDAQ:AXON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Axovant Sciences (NASDAQ AXON) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.